Targeting opioid dysregulation in depression for the development of novel therapeutics
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Since the serendipitous discovery of the first class of modern antidepressants in the 1950’s, all pharmacotherapies approved by the Food and Drug Administration for major depressive disorder (MDD) have shared a common mechanism of action, increased monoaminergic neurotransmission. Despite the widespread availability of antidepressants, as many as 50% of depressed patients are resistant to these conventional therapies. The significant length of time required to produce meaningful symptom relief with these medications, 4–6 weeks, indicates that other mechanisms are likely involved in the pathophysiology of depression and these mechanisms may yield more viable targets for drug development. For decades, no viable candidate target with a different mechanism of action to that of conventional therapies proved successful in clinical studies. Now several exciting avenues for drug development are under intense investigation. One of these emerging targets is modulation of endogenous opioid tone. This review will evaluate preclinical and clinical evidence pertaining to opioid dysregulation in depression focusing on the role of the endogenous ligands endorphin, enkephalin, dynorphin, and nociceptin/orphanin FQ (N/OFQ) and their respective receptors, mu (MOR), delta (DOR), kappa (KOR), and the N/OFQ receptor (NOP) in mediating behaviors relevant to depression and anxiety. Finally, putative opioid based antidepressants that are being tested in clinical trials, ALKS5461, JNJ–67953964 (formerly LY2456302 and CERC–501) and BTRX–246040 (formerly LY–2940094) will be discussed. This review will illustrate the potential therapeutic value of targeting opioid dysregulation in developing novel therapies for major depression disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Endogenous opioid peptides: multiple agonists and receptors
Lord, J. A. H., Waterfield, A. A., Hughes, J., & Kosterlitz, H. W. (1977) · Nature · doi:10.1038/267495a0 · Cited by 2,485
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 2×
“Moreover, aberrant neuronal firing and synaptic plasticity deficits are characteristic features of rodent models of stress and depression (Duman & Aghajanian, 2012; Howe & Kenny, 2018; Lutz & Kieffer, 2013; Ota & Duman, 2013).”
BackgroundThe NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry
Insel, T. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020138 · Cited by 1,472 · cited 2×
“As MDD encompasses a heterogeneous cluster of behavioral symptoms, section 2 of this review will critically evaluate the contribution of opioid receptors in modulating behavioral domains as defined by the NIMH research domain criterion (RDoC) (Insel, 2014), which target specific endophenotypes shared across multiple d…”
BackgroundLai, H. M. X., Cleary, M., Sitharthan, T., & Hunt, G. E. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.05.031 · Cited by 941
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Di Chiara, G., & Imperato, A. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24578-5 · Cited by 916
Psychotomimesis Mediated by κ Opiate Receptors
Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M. (1986) · Science · doi:10.1126/science.3016896 · Cited by 857
Drug dependence: stress and dysregulation of brain reward pathways
Kreek, M. J., & Koob, G. F. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00064-7 · Cited by 696
Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses
Filliol, D., Ghozland, S., Chluba, J., Martin, M., Matthes, H. W. D., Simonin, F., Befort, K., Gavériaux-Ruff, C., Dierich, A., LeMeur, M., et al. (2000) · Nature Genetics · doi:10.1038/76061 · Cited by 672
Cited by
Molecular pathways of major depressive disorder converge on the synapse
Fries, G. R., Saldana, V. A., Finnstein, J., & Rein, T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01806-1 · Cited by 504
New approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226
Pérez de la Mora, M., Borroto-Escuela, D. O., Crespo-Ramírez, M., Rejón-Orantes, J. D. C., Palacios-Lagunas, D. A., Martínez-Mata, M. K., Sánchez-Luna, D., Tesoro-Cruz, E., & Fuxe, K. (2022) · Cells · doi:10.3390/cells11111826 · Cited by 21
Metadata
- Authors
- Browne, C. A., & Lucki, I.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 201
- Pages
- 51-76
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2942936997
- Cited by
- 95
- References
- 62
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting opioid dysregulation in depression for the development of novel therapeutics. https://app.cochat.ai/papers/10.1016/j.pharmthera.2019.04.009
- The paper
- Browne, C. A., & Lucki, I. (2019). Targeting opioid dysregulation in depression for the development of novel therapeutics. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2019.04.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.